Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01953432 · ClinicalTrials.gov registry record · Phase 2
Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT01953432: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT01953432 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01953432, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
Cocaine use disorders affect approximately 1.5 million Americans annually. Currently, there are no US Food and Drug Administration approved medications for treatment of cocaine dependence; however, both animal and human studies suggest that medications affecting the noradrenergic system can reduce cocaine craving and use. The investigators will study the effect of doxazosin, an alpha-1 adrenergic antagonist, in reducing cocaine use and anxiety symptoms among cocaine-dependent individuals. In addition, the investigators will identify genetic subpopulations of participants who preferentially respond to the medication.
Interventions
- DRUG Placebo
- DRUG Doxazosin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-04-01 |
| Est. Completion | 2017-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01953432
The ClinicalTrials.gov registry entry for NCT01953432 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01953432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01953432 about?
NCT01953432 is a clinical study titled "Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse". Cocaine use disorders affect approximately 1.5 million Americans annually. Currently, there are no US Food and Drug Administration approved medications for treatment of cocaine dependence; however, both animal and human studies suggest that medications affecting the noradrenergic system can reduce c...
What is the current status of trial NCT01953432?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2014-04-01. Estimated completion is 2017-10-01.
What interventions are being tested in trial NCT01953432?
The interventions under investigation include: Placebo (DRUG), Doxazosin (DRUG).
Who is sponsoring clinical trial NCT01953432?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.